share_log
Moomoo 24/7 ·  Apr 4 09:17
EFFECTOR Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From the Primary Analysis of the Randomized Phase 2 KICKSTART Trial of Tomivosertib Combined With Pembrolizumab in Non-small Cell Lung Cancer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment